Centessa Pharmaceuticals (CNTA) Change in Acquisitions & Divestments (2023 - 2026)

Centessa Pharmaceuticals (CNTA) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $118.2 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 57.48% year-over-year to $118.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $364.8 million (up 73.56% YoY) and the FY2025 annual result came in at $321.6 million, up 87.16% from the prior year.
• Change in Acquisitions & Divestments advanced to $118.2 million in Q1 2026 per CNTA's latest filing, from $95.6 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $118.2 million in Q1 2026 and bottomed at $25.0 million in Q4 2024.
• The 4-year median for Change in Acquisitions & Divestments is $65.1 million (2024), against an average of $68.2 million.
• The widest annual swing landed in 2024, when Change in Acquisitions & Divestments plunged 51.76%; it then surged 282.36% in 2025.
• Tracing CNTA's Change in Acquisitions & Divestments over 4 years: stood at $51.8 million in 2023, then sank by 51.76% to $25.0 million in 2024, then surged by 282.36% to $95.6 million in 2025, then grew by 23.7% to $118.2 million in 2026.
• Per Business Quant, the three latest CNTA Change in Acquisitions & Divestments figures stand at $118.2 million (Q1 2026), $95.6 million (Q4 2025), and $107.7 million (Q3 2025).

Peer Comparison